RU-58841 For HAIR LOSS: Is It The "Miracle Drug"?

Описание: The Truth About Hair Loss -    • Hair Loss Industry Exposed! - How I regrew...  

Wondering if RU-58841 for hair loss is all it's made out to be? Well in this video, we'll be doing an in-depth review for you!

📌 00:00 - Intro
📌 00:46 - The Story of RU58841
📌 2:34 - Further story of RU58841 research
📌 5:11 - Side Effects
📌 6:12 - How do you purchase RU58841
📌 6:50 - Our Verdict

Transcription

The Story of RU58841

So RU58841 is not a recent drug.

It was first developed in the 1970s by French scientists.

They were looking into treatments for prostate cancer.

But after testing it on rats, they found it promoted hair growth.

RU58841 is a quote, “non-steroidal anti-androgen”.

So it inhibits the action of androgens, including DHT. And the way it does this is by binding to the
androgen receptor.

When it binds, it doesn’t activate it, like DHT. It just blocks it, so that DHT and the other androgens
can’t activate it.

Now as I said, RU58841 started getting serious attention when it was observed to promote hair
growth in rodents.

And further animal studies in the 90s confirmed it could also grow hair topically.

Reportedly, this could be achieved at a third of the dose required to produce systemic side
effects.

So the drug had significant topical activity, even at low doses.

And the animal results were very, very, promising.

Most of the research was done on stumptailed macaques

These are a species of monkeys that can go bald, and in a similar pattern to men. So they’re often used as a proxy for humans in hair loss research.

In the first study, macaques were treated with oral finasteride or topical RU58841. On average, the RU increased follicles in the anagen growth phase by 103%,. This compared to 88% with finasteride.

Namely 5%, 3%, 1% and 0.5%. Treatment lasted up to 2 years.

It was found that the 5% solution gave the best results, and these started to show after 3 months.
Overall, the macaques in the 5% group had denser, thicker and longer hair.

The 3% and lower solutions weren’t powerful enough to give good or consistent results.

***

A few years later, a company called Prostrakan acquired the rights to RU58841.

It was then renamed to PSK3841.

To keep things simple, we’ll just call it RU in this video, which is what everyone still calls it.

So Prostrakan did two clinical trials on humans in the early 2000s.

The first was a phase I study to assess its safety. It was done in France.

30 men with male pattern baldness applied 5% solution on their head twice a day, for 4 weeks.

To the best of our knowledge the results of this study were never made public. But they must
have been good, because the company then ran a phase II trial.

The phase 2 trial compared placebo to two solutions of RU58841: a 2.5% and a 5% strength.

The total sample size was 120 balding men. They were treated over 6 months.

Again, this study was never published, so we don’t have the full results. But according to what got
out, the results were as good as what you get with finasteride, if not better.

After these successful trials, the company planned to go ahead with a phase III trial.

But this never happened, and to this day nobody knows exactly why.

Some say it’s because the drug is too unstable, and has a limited shelf life.

But we doubt that’s the case. The solution is stable for up to a year in low temperatures.

Which is way longer than it takes a bottle to be used up.

Of course you have to account for the time it takes to reach the consumer from the point of
production, but still.

If the shelf life was an unsolvable problem, it’s unlikely Prostrakan would have ever invested the money to run two expensive trials in humans.

Resources

http://www.isrctn.com/ISRCTN71083772
http://www.isrctn.com/ISRCTN49873657
https://www.infona.pl/resource/bwmeta...
https://www.infona.pl/resource/bwmeta...
https://link.springer.com/article/10....

-------------------------------

Disclaimer

This video is for educational purposes only and is not intended to treat, diagnose or cure any disease.